Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAG | P20916 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15143133 | 0.89 | L3MBTL1 (0.50) | L3MBTL1POLBMAGLMNAKMT2A | |
| SCHEMBL15143128 | 0.86 | L3MBTL1 (0.50) | L3MBTL1POLBMAGLMNAKMT2A | |
| SCHEMBL15480298 | 0.84 | NAAA (0.38) | POLBSSTR5SSTR1SSTR2SSTR4 | |
| SCHEMBL16640651 | 0.81 | SLC6A2 (0.40) | SSTR5SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL7150281 | 0.81 | POLB (0.50) | L3MBTL1POLBMAGHRASMAPK1 | |
| SCHEMBL7150277 | 0.81 | POLB (0.50) | L3MBTL1POLBMAGHRASMAPK1 | |
| SCHEMBL14520980 | 0.81 | MAPK1 (0.58) | POLBKMT2AHRASMAPK1 | |
| SCHEMBL20643560 | 0.81 | MAPK1 (0.58) | POLBKMT2AHRASMAPK1 | |
| SCHEMBL21097246 | 0.81 | MAPK1 (0.58) | POLBKMT2AHRASMAPK1 | |
| SCHEMBL542635 | 0.81 | MAPK1 (0.58) | POLBKMT2AHRASMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150104479-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | NOVARTIS AG (CH) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150104479-A1 | MENINGOCOCCUS SEROGROUP X CONJUGATE | O60361, MLEC, PDHX | L3MBTL1 3101/4885POLB 2095/4885MAG 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.